印度霍乱控制政策路径
本文讨论印度霍乱地方性流行背景下口服灭活霍乱疫苗已获WHO预认证并由Gavi联盟储备,但尚未用于公共卫生项目。国家免疫技术咨询组(NTAGI)正考虑霍乱疫苗,需综合疾病负担、疫苗性能、成本效果及WHO建议制定控制政策。
要点
- 口服灭活霍乱疫苗已获WHO预认证并在印度获许可,但未用于公共卫生项目。
- NTAGI综合疾病负担、疫苗性能、成本效果和WHO建议评估霍乱疫苗引入。
- 印度急需霍乱控制政策,疫苗可及性和可负担性提供新机遇。
核心结论
- 印度急需霍乱控制政策,口服霍乱疫苗的可及性和可负担性为控制这一重要公共卫生问题提供新机遇。
研究设计与样本
- 本文为政策分析类文章,未报告系统检索或原始研究设计。
主要发现
- 霍乱在东南亚呈地方性流行,现有控制机制未应用或无效。
- 口服灭活霍乱疫苗已获WHO预认证并由Gavi联盟储备。
- 霍乱疫苗在印度已测试、生产并获许可数年,但未用于地方性流行或暴发的公共卫生项目。
关键数值与推荐
- NTAGI是向卫生部报告的咨询机构,考虑疾病负担、疫苗性能、成本效果和引入国家项目的潜力,并参考WHO建议。
临床怎么用
- 公共卫生决策者可依托NTAGI评估框架,结合WHO建议和本地证据推进霍乱疫苗引入。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cholera is endemic in southern Asia, but available control mechanisms have either not been applied or have been ineffective. Oral killed cholera vaccines are now available, are pre-qualified by the World Health Organization (WHO) and are being stock-piled by the Gavi Alliance. Although cholera vaccines have been tested, manufactured and licensed in India for several years, they are not in use in public health programmes for either endemic disease or outbreaks. The National Technical Advisory Group on Immunization (NTAGI) is the advisory body that considers disease burden, vaccine performance, cost-effectiveness and potential for introduction into national programmes, reporting to the Ministry of Health. The NTAGI also takes into account the recommendations of the WHO and is now considering cholera vaccines. Policies for cholera control are urgently needed, and the availability and affordability of an oral cholera vaccine in India offers new opportunities to control an important public health problem.
引用
- Sekhar A, Kang G. Pathways to a policy for cholera control in India. Vaccine. 2019. PMID: 31266672. doi:10.1016/j.vaccine.2019.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。